Dasatinib for treatment of CAR T-cell therapy-related complications. Issue 12 (1st December 2022)

• Record Type: Journal Article
• Authors: Baur, Katharina; Heim, Dominik; Beerlage, Astrid; Poerings, Anna S; Kopp, Bastian; Medinger, Michael; Dirks, Jan C; Passweg, Jakob R; Holbro, Andreas
• Is Part Of: Journal for immunotherapy of cancer. Volume 10:Issue 12(2022)
• Publication Date: 2022-12-01
• Subjects: Case Reports -- Cytokines -- Adjuvants, Pharmaceutic; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2022-005956
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse. Therefore, additional treatment options need to be explored. We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies.